Back to 
Barclays plc
Barclays plc
MCRB
4 quarters
Position history for Barclays plc's holdings in Seres Therapeutics, Inc.
Yes. Barclays holds 167 shares of MCRB (Seres Therapeutics), worth $1,318, as of its Q2 2026 13F filing. It reduced the position by 6,340 shares (-97.4%) from Q1 2026. Barclays has held MCRB since Q3 2025, across 4 quarterly 13F filings.
Current Value
$1,318
Current Shares
167
Total Value Change
-$25,772
Total Shares Change
-1,241
Quarter-by-Quarter History
Other major holders of MCRB: Vanguard Group Inc., FMR LLC, Susquehanna International Group, LLP